Table II. Relative risk of non-Hodgkin lymphoma (NHL) after first primary solid cancer according to initial radiotherapy treatment.
| Radiotherapy | No Radiotherapy | Radi otherapy vs. No Radiotherapy | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||
| First Primary Cancer | Obs | Exp | SIR | Obs | Exp | SIR | RR* | 95% CI |
|
|
|
|
||||||
| All solid cancers | 1.742 | 1,613.75 | 1.08 | 3,848 | 3,924.46 | 0.98 | 1.13 | (1.06-1.20) |
| All standard radiotherapy treated solid cancers† | 1,545 | 1,504.52 | 1.03 | 2,191 | 2,446.86 | 0.90 | 1.14 | (1.07-1.22) |
| Oral cavity & pharynx | 73 | 58.88 | 1.24 | 92 | 77.87 | 1.18 | 0.87 | (0.60-1.25) |
| Larynx | 59 | 57.70 | 1.02 | 23 | 18.59 | 1.24 | 0.89 | (0.54-1.46) |
| Thyroid | 45 | 32.81 | 1.37 | 47 | 51.00 | 0.92 | 1.29 | (0.84-1.98) |
| Lung & bronchus (NSC) | 62 | 52.93 | 1.17 | 135 | 151.85 | 0.89 | 1.53 | (1.08-2.17) |
| Female breast | 355 | 416.07 | 0.85 | 586 | 665.29 | 0.88 | 0.97 | (0.84-1.10) |
| Cervix uteri | 30 | 23.63 | 1.27 | 33 | 26.57 | 1.24 | 1.03 | (0.57-1.86) |
| Endometrium | 93 | 92.48 | 1.01 | 144 | 181.37 | 0.79 | 1.26 | (0.96-1.65) |
| Prostate | 728 | 684.60 | 1.06 | 991 | 1,102.58 | 0.90 | 1.19 | (1.08-1.32) |
| Testis | 22 | 17.46 | 1.26 | 10 | 14.99 | 0.67 | 1.57 | (0.69-3.55) |
| Rectum & rectosigmoid junction | 78 | 67.97 | 1.15 | 130 | 156.76 | 0.83 | 1.29 | (0.88-1.88) |
Abbreviations: NSC, non-small cell; Obs, observed; Exp, expected; SIR, standardi zed incide nce ratio; RR, relative risk; CI, confide nce interval
*
Poisson regression modeling used to estimate RR of NHL comparing radiotherapy treatment groups for first primary cancer adjusted by sex, age, stage, and chemotherapy.
†
Includes oral cavity & pharynx, rectosigmoid junction & rectum, larynx, lung & bronchus (NSC), female breast, cervix uteri, endometrial, prostate, testis, and thyroid cancers.